

COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and clinical-stage antiviral therapeutics that target the replication process of influenza virus, norovirus, coronavirus and hepatitis C virus.

RECENT NEWS

Cocrystal Pharma, Inc. Announces Up To \$13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12 2025, 9:43 AM EDT

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Sep 12 2025, 8:00 AM EDT

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 8 2025, 8:00 AM EDT

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	16.21m
Last Price	\$1.58
52-Week Range	\$1.12 - \$3.26

09/12/2025 08:00 PM EDT

INVESTOR RELATIONS

Alliance Advisors IR
Jody Cain
T: 310-691-7100
jcain@allianceadvisors.com

MANAGEMENT TEAM

Sam Lee, Ph.D.

Co-Chief Executive Officer and President

James J. Martin

Co-Chief Executive Officer and Chief Financial Officer

COCRYSTAL PHARMA, INC.

19805 North Creek Parkway
Bothell, WA 98011
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.